Form 4 for ACRS Aclaris Therapeutics, Inc.
Accepted 2023-06-05 00:00:00 ET · period of report 2023-06-01 · accession 0001209191-23-034477 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-06-05 | 2023-06-02 | ACRS | Humphries William D. | Dir | M - OptEx | — | +4,507 | 24.1K | +23% | — |
| DM | 2023-06-05 | 2023-06-01 | ACRS | Humphries William D. | Dir | A - Grant | $0.00 | +20.4K | 15.8K | New | $0 |
| D | 2023-06-05 | 2023-06-02 | ACRS | Humphries William D. | Dir | M - OptEx | $0.00 | -4,507 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-06-02 | M | A | 4,507 | — | 24,072 | D | — | — | (F1) Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. |
| 2 | Derivative | Restricted Stock Units | 2023-06-01 | A | A | 4,660 | $0.00 | 4,660 | D | — · — to — | 4,660 Common Stock | (F1) Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. (F4) The shares underlying these restricted stock units will vest on June 1, 2024, subject to the Reporting Person's continuous service through such date. (F2) This grant was made pursuant to the issuer's ninth amended and restated non-employee director compensation policy. |
| 3 | Derivative | Restricted Stock Units | 2023-06-02 | M | D | 4,507 | $0.00 | 0 | D | — · — to — | 4,507 Common Stock | (F1) Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer. (F5) The shares underlying these restricted stock units vested on June 2, 2023. |
| 4 | Derivative | Stock Option (Right to Buy) | 2023-06-01 | A | A | 15,750 | $0.00 | 15,750 | D | $8.70 · — to 2033-05-31 | 15,750 Common Stock | (F2) This grant was made pursuant to the issuer's ninth amended and restated non-employee director compensation policy. (F3) The shares subject to this option will vest in twelve equal monthly installments commencing July 1, 2023, subject to Reporting Person's continuous service through each such date. |